High serum apolipoprotein e determines hypertriglyceridemic dyslipidemias, coronary disease and ApoA-I dysfunctionality

Lipids

Volumn 48, Issue 1, 2013, Pages 51-61

  Onat, Altan ^a   Can, Günay ^a   Örnek, Ender ^b   Ayhan, Erkan ^c   Erginel Ünaltuna, Nihan ^a   Murat, Sani N ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Etlik Ihtisas Education Hospital   (Turkey)

^c BALIKESIR UNIVERSITY   (Turkey)

Author keywords

Apolipoprotein A I; Apolipoprotein B; Apolipoprotein E concentrations; Atherogenic dyslipidemia; Coronary heart disease; Hypertriglyceridemia with elevated apoB

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GENOTYPE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOBETALIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; NEPHELOMETRY; OXIDATIVE STRESS; PREDICTIVE VALUE; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; APOLIPOPROTEINS E; C-REACTIVE PROTEIN; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84872348887     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-012-3724-8     Document Type: Article

References (33)

1. Mahley RW, Ji ZS (1999) Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 10:1-16
2. Dallongeville J, Lussier-Cacan S, Davignon S (1992) Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 33:447-454
3. Bennet AM, Di Angelantonio E, Ye Z et al (2007) Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298:1300-1311
4. Dominczak MH, Caslake MJ (2011) Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem 48:498-515
5. Huang Y (2010) Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological disease. Curr Opin Lipidol 21:337-345
6. Onat A, Hergenç G, Ayhan E et al (2007) Serum apolipoprotein E concentrations among Turks: additive information to genotype relative to dyslipidemia and metabolic syndrome. Arch Turk Soc Cardiol 35:449-457
7. Söderlund S, Watanabe H, Ehnholm C et al (2010) Increased apolipoprotein E level and reduced high-density lipoprotein mean particle size associate with low high-density lipoprotein cholesterol and features of metabolic syndrome. Metabolism 59:1502-1509
8. Mooijaart SP, Berbée JFP, van Heemst D et al (2006) ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med 3:e176
9. Corsetti JP, Bakker SJ, Sparks CE, Dullaart RP (2012) Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease in women with high levels of HDL cholesterol and C-reactive protein. PLoS One 7:e39110
10. Onat A, Can G, Ayhan E et al (2009) Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 58:1393-1399
11. Onat A, Hergenç G (2011) Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 60:499-512
12. Onat A, Hergenç G, Bulur S et al (2010) The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 142:72-79
13. Onat A, Kömürcü-Bayrak E, Can G et al (2010) Apolipoprotein A-I positively associated with diabetes in women independently of apoE genotype and apolipoprotein B levels. Nutrition 26:975-980
14. Packard CJ, Ford I, Robertson M et al (2005) Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the prospective study of pravastatin in the elderly at risk. (PROSPER). Circulation 112:3058-3065
15. Ray KK, Cannon CP, Cairns CP et al (2009) Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 29:424-430
16. Onat A (2001) Risk factors and cardiovascular disease in Turkey. Atherosclerosis 156:1-10
17. Grundy SM, Brewer HB, Cleeman JI et al (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433-438
18. Onat A, Uyarel H, Hergenç G et al (2007) Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 191:182-190
19. Genuth S, Alberti KG, Bennett P et al (2003) Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. The expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26:3160-3167
20. Mather KJ, Hunt AE, Steinberg HO et al (2001) Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 86:5457-5464
21. Rose GA, Blackburn H, Gillum RF et al (1982) Cardiovascular survey methods, 2nd edn. WHO, Geneva, pp 124-127
22. Greenow K, Pearce NJ, Ramji DP (2005) The key role of apolipoprotein E in atherosclerosis. J Mol Med 83:329-342
23. Onat A, Can G, Hergenç G et al (2007) Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes 31:1119-1125
24. Sniderman A, Scantlebury T, Cianflone K (2001) Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135:447-459
25. Janis MT, Metso J, Lankinen H et al (2005) Apolipoprotein activates the low-activity form of human phospholipid transfer protein. Biochem Biophys Res Commun 331:333-340
26. Francis GA (2010) The complexity of HDL. Biochim Biophys Acta 1801:1286-9324b
27. Vaisar T, Pennathur S, Green PS et al (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117:746-756
28. Park KH, Shin DG, Kim JR et al (2010) The functional and compositional properties of lipoproteins are altered in patients with metabolic syndrome with increased cholesteryl ester transfer protein activity. Int J Mol Med 25:129-136
29. Haase CL, Tybjaerg-Hansen A, Grande P et al (2010) Genetically elevated apolipoprotein A-I, high-density lipoprotein levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 95:E500-E510
30. Barbagallo CM, Rizzo M, Noto D et al (2006) Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. Metabolism 55:662-668
31. Van den Elzen P, Garg S, Léon L et al (2005) Apolipoprotein- mediated pathways of lipid antigen presentation. Nature 437:906-910
32. Ogasawara K, Mashiba S, Hashimoto H et al (2008) Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta 397:42-47
33. Cigliano L, Pugliese CR, Spagnuolo MS et al (2009) Haptoglobin binds the antiatherogenic protein apolipoprotein E - impairment of apolipoprotein E stimulation of both lecithin: cholesterol acyltransferase activity and cholesterol uptake by hepatocytes. FEBS J 276:6158-6171